Low disease activity versus remission in SLE: is it ok to be “mediocre”?

Comment on: Petri M, Madger LS. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. Arthritis Rheum 2018; 1790– 1795 Commented by: Laurent Arnaud, Department of Rheumatology, National Reference Centre for Rare Systemic and Autoimmune Diseases East South-West (RESO), Strasbourg, France. Twitter: @Lupusreference. Email: Laurent.arnaud@chru-strasbourg.fr … Read more

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

Comment on: Fanouriakis A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736-45. Commented by: Nathalie Costedoat-Chalumeau, Internal Medicine Department, Cochin Hospital, Referral center for rare autoimmune and systemic diseases, Paris, France. The 2008 EULAR recommendations for the management of systemic lupus erythematosus (SLE) have … Read more

Lupus quality of care: Unmet needs for bridging the gaps across multiple healthcare settings

Comment on: Aggarwal I, Li J, Trupin L, Gaynon L, Katz PP, Lanata C, Criswell L, Murphy LB, Dall’Era M, Yazdany J. Quality of Care for the Screening, Diagnosis, and Management of Lupus Nephritis Across Multiple Healthcare Settings. Arthritis Care Res (Hoboken) 2019 May 6. doi: 10.1002/acr.23915. [Epub ahead of print] Link: https://onlinelibrary.wiley.com/doi/abs/10.1002/acr.23915 Commented by: … Read more

Improving mortality of SLE patients: How far did we progress?

Comment on: Tselios K, Gladman DD, Sheane BJ, Su J, Urowitz M. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). Annals of the Rheumatic Diseases 2019; 78 (6): 802-806. Link: https://ard.bmj.com/content/78/6/802.long Commented by: Luís Inês, MD, PhD. Rheumatologist, CHUC Lupus Clinic, Rheumatology Dpt., … Read more